In this study, we aim to compare the anatomical and functional outcomes of intravitreal anti-VEGF agents and oral CAIs, evaluating their efficacy, duration of action, and complications in treating CME in RP eyes. The gene discussed is VEGFA; the disease is retinitis pigmentosa 1.